> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Hospira Recall Over Glass Particulates
- URL: https://www.fdaweb.com/hospira-recall-over-glass-particulates/
- Published: 2023-10-03T12:00:00.000Z
- Updated: 2026-09-14T18:59:56.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155475

Pfizer’s Hospira drug unit is recalling several drug lots of 4.2% sodium bicarbonate injection, USP, 5 mEq/10mL vial; 1% lidocaine HCl injection, USP, 50 mg/5mL vial; and 2% lidocaine HCl injection, USP, 100 mg/5mL vial due to the potential presence of glass particulate matter.

“There is an unlikely probability for serious adverse events, including death, should a patient receive an injectable product found to contain particulate matter identified as glass,” a recall notice says. “Potential complications related to injection of visible and subvisible inert particles include inflammation of a vein, granuloma, and blockage of blood vessels or life-threatening blood clot events.”

To date, Hospira says it has not received reports of any adverse events associated with the issue.